1. Home
  2. GLOB vs RAPP Comparison

GLOB vs RAPP Comparison

Compare GLOB & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Globant S.A.

GLOB

Globant S.A.

N/A

Current Price

$36.24

Market Cap

1.3B

Sector

Technology

ML Signal

N/A

Logo Rapport Therapeutics Inc.

RAPP

Rapport Therapeutics Inc.

N/A

Current Price

$30.87

Market Cap

1.5B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
GLOB
RAPP
Founded
2003
2022
Country
Luxembourg
United States
Employees
N/A
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.5B
IPO Year
2015
2024

Fundamental Metrics

Financial Performance
Metric
GLOB
RAPP
Price
$36.24
$30.87
Analyst Decision
Buy
Strong Buy
Analyst Count
23
14
Target Price
$51.23
★ $63.04
AVG Volume (30 Days)
★ 820.9K
410.4K
Earning Date
11-12-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 24.34
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.08
N/A
P/E Ratio
$22.55
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$27.56
$23.75
52 Week High
$72.10
$52.93

Technical Indicators

Market Signals
Indicator
GLOB
RAPP
Relative Strength Index (RSI) 49.85 27.01
Support Level $35.68 $26.08
Resistance Level $38.88 $31.57
Average True Range (ATR) 1.34 2.30
MACD 0.19 -0.25
Stochastic Oscillator 56.82 12.40

Price Performance

Historical Comparison
GLOB
RAPP

About GLOB Globant S.A.

Globant is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2003 in Argentina but is currently headquartered in Luxembourg and primarily serves clients in the US and Latin America. Globant's client base is relatively concentrated in the media and entertainment and financial services industries.

About RAPP Rapport Therapeutics Inc.

Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Share on Social Networks: